Alvotech and bioventure announce approval of avt02 (adalimumab) as simlandi in saudi arabia

Alvotech (nasdaq: alvo) and bioventure, a wholly owned subsidiary of globalone healthcare holding llc (“ghh”), the healthcare division of yas holding llc, today announced that the saudi food & drug authority (“sfda”) has approved the manufacturing and distribution of avt02, a biosimilar for humira® (adalimumab), which is commonly indicated for the treatment of rheumatoid arthritis and several other inflammatory diseases. the biosimilar will be marketed as simlandi™ in saudi arabia.
ALVO Ratings Summary
ALVO Quant Ranking